GORDON ZEIS: Open Payments
NPI 1568935864 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,078 in 160 payments from 14 companies in 2025. Trend: 2023 $1,318 · 2024 $2,146 · 2025 $4,078
Food & beverage: $3,855Education: $223
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 26 | $736 |
| Alkermes, Inc. | 20 | $559 |
| Janssen Pharmaceuticals, Inc | 16 | $558 |
| Otsuka America Pharmaceutical, Inc. | 20 | $517 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $382 |
| ABBVIE INC. | 21 | $341 |
| Lundbeck LLC | 10 | $232 |
| Braeburn Inc. | 5 | $202 |
| E.R. Squibb & Sons, L.L.C. | 7 | $174 |
| Vanda Pharmaceuticals Inc. | 7 | $141 |
Products named: REXULTI, INVEGA SUSTENNA, CAPLYTA, VRAYLAR, LYBALVI, UZEDY, AUSTEDO XR, ARISTADA.
Industry payments across PA — which companies pay providers there.
